KRAS and neoplasm: For the optimum selection of eligible patients, initial molecular data established mutations of genes encoding effector proteins downstream of EGFR in the tumor signaling cascade, primarily mutations in codon 12 or 13 of KRAS, as predictor of intrinsic therapeutic resistance to anti-EGFR monoclonal antibodies [9].